| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $104.9M | +11.8% |
| SG&A Expense | $18.9M | -6.3% |
| Operating Income | -$123.8M | -8.6% |
| Income Tax | $0 | — |
| Net Income | -$121.3M | -18.6% |
| EPS (Basic) | -$2.00 | -17.0% |
| EPS (Diluted) | -$2.00 | -17.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $54.0M | +51.5% |
| Short-term Investments | $62.9M | -53.7% |
| Current Assets | $122.3M | -31.4% |
| Total Assets | $122.8M | -48.6% |
| Current Liabilities | $30.0M | +8.7% |
| Long-term Debt | $22.4M | -23.9% |
| Total Liabilities | $52.4M | -8.3% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$115.5M | -34.0% |
| Investing Cash Flow | $133.9M | +178.9% |
| Financing Cash Flow | -$34K | -100.5% |
| $70.4M |
| -61.3% |